Biohaven reports positive patient data for autoimmune disease drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Raymond James on Biohaven Pharma (BHVN) with shares up 7%: 'Promising Degrader Data Sets Ahead of R&D Day'
May 27, 2026 10:16 AM EDTRaymond James analyst Chris Raymond reiterated a Strong Buy rating and $50.00 price target on Biohaven Pharma (NYSE: BHVN).
The analyst comments "Remain Strong Buy rated on BHVN shares following the announcement of positive preliminary data sets for degraders BHV-1300 and BHV-1400 in patients this morning... More
